OPK Stock Cash Flow Statements

OPKO Health Quarterly Cash Flow Statements Chart

Quarterly

Annual

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

OPKO Health Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-09-30	2019-06-30	2019-03-31	2018-09-30	2018-06-30	2018-03-31	2017-09-30	2017-06-30	2017-03-31	2016-09-30	2016-06-30	2016-03-31	2015-09-30	2015-06-30	2015-03-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31

cash flows from operating activities:
net income	-148,441,000	-67,613,000	24,890,000	-10,305,000	-81,836,000	-66,483,000	-84,473,000	-19,640,000	-18,267,000	-85,231,000	-86,091,000	-101,650,000	-55,433,000	-73,774,000	28,739,000	-16,186,000	31,078,000	32,298,000	23,717,000	33,703,000	-59,132,000	-62,007,000	-59,806,000	-80,762,000	-27,654,000	-6,201,000	-43,114,000	-46,442,000	-17,528,000	-30,995,000	-14,977,000	15,532,000	-11,978,000	128,247,000	-43,241,000	-118,037,000	-50,013,000	-26,072,000	-45,091,000	-17,430,000	-60,801,000	-4,353,000	-34,762,000	-1,040,000	-9,646,000	-10,243,000	-8,611,000			-5,746,000	-5,704,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	23,027,000	23,487,000	24,163,000	24,154,000	25,820,000	25,982,000	26,322,000	26,547,000	26,446,000	26,460,000	26,386,000	27,995,000	27,814,000	19,191,000	18,964,000	20,572,000	19,989,000	20,067,000	20,977,000	22,266,000	22,052,000	23,804,000	23,661,000	23,816,000	23,922,000	24,761,000	24,757,000	25,396,000	25,551,000	25,730,000	25,832,000	24,581,000	22,199,000	12,388,000	4,160,000	3,525,000	3,678,000	4,027,000	3,564,000	4,568,000	3,768,000	3,451,000	3,429,000	2,713,000	2,665,000	2,454,000	2,328,000	972,000	776,000	1,085,000	997,000
non-cash interest	56,908,000	4,649,000	4,615,000	4,295,000	3,843,000	693,000	693,000	686,000	678,000	693,000	693,000	686,000	678,000	2,225,000	2,183,000	2,396,000	2,585,000	2,355,000	2,617,000	2,539,000	2,483,000	1,690,000	-142,000	3,010,000	1,361,000	1,355,000	843,000	650,000	654,000	640,000	655,000	659,000	749,000
amortization of deferred financing costs	4,529,000	430,000	382,000	427,000	519,000	314,000	310,000	302,000	296,000	298,000	294,000	288,000	281,000	182,000	179,000	202,000	222,000	221,000	215,000	208,000	203,000	198,000	-97,000	405,000	56,000	56,000	43,000	56,000	56,000	56,000	101,000	37,000	37,000	280,000	144,000	751,000	100,000	1,630,000	177,000	177,000	650,000	198,000	145,000
losses from investments in investees	0	9,000	4,000	0	3,000	8,000	20,000	42,000	37,000	24,000	43,000	267,000	49,000	466,000	53,000	67,000	43,000	47,000	110,000	189,000	134,000	294,000	271,000	1,854,000	1,873,000	7,213,000	2,456,000	4,013,000	5,627,000	2,131,000	814,000	1,988,000	2,345,000	3,502,000	804,000	1,761,000	60,000	370,000	2,056,000	3,595,000	1,600,000	2,371,000	3,890,000
equity-based compensation – employees and non-employees	2,212,000	2,616,000	2,784,000	2,609,000	2,590,000	2,667,000	3,219,000	2,810,000	2,717,000	3,194,000	3,390,000	4,308,000	7,617,000	3,703,000	3,822,000	3,460,000	2,647,000	2,170,000	2,740,000	1,586,000	2,451,000	3,428,000	3,122,000	4,457,000	5,077,000	5,578,000	5,936,000	6,448,000	6,151,000	9,693,000	8,834,000	8,798,000	17,307,000	3,675,000	6,708,000	7,382,000	3,095,000	3,414,000	3,579,000	3,572,000	408,000	1,798,000	5,205,000				1,180,000
realized gain on disposal of fixed assets and sales of equity securities	-72,000	-3,786,000	-9,420,000	-22,000	-47,000					359,000	-337,000	-538,000	61,000	1,562,000	-32,338,000	-107,000	-3,039,000
change in fair value of equity securities and derivative instruments	-646,000	2,380,000	-35,378,000	-60,499,000	1,251,000	3,241,000	8,260,000	13,276,000	-7,130,000	49,709,000	30,402,000	72,425,000	1,299,000	2,048,000	1,046,000	1,152,000	-279,000		7,768,000	-15,774,000	9,259,000	11,747,000	7,256,000	-1,825,000	473,000	-11,718,000	-3,101,000
inducement expense and loss on debt conversion
deferred income tax benefit	-15,713,000	-7,424,000	12,172,000	-1,797,000	-2,680,000		5,554,000	1,651,000	102,000		-39,941,000	13,414,000	-22,356,000								613,000	1,897,000	520,000	-352,000	-12,515,000	683,000	-2,709,000	-23,327,000	-13,803,000	-9,236,000	-21,983,000	13,245,000	-22,244,000								405,000	-700,000	98,000
changes in assets and liabilities:
accounts receivable	-3,815,000	22,930,000	327,000	5,835,000	9,518,000	-5,330,000	90,563,000	-89,186,000	7,364,000	-1,450,000	34,188,000	51,443,000	44,421,000	-22,702,000	7,582,000	55,590,000	-35,238,000	-43,182,000	-25,716,000	-80,776,000	-763,000	7,655,000	-3,959,000	-439,000	-4,739,000	5,683,000	6,757,000	17,271,000	-13,094,000	-17,771,000	-10,586,000	-8,464,000	-9,924,000	-9,200,000	-4,709,000	-103,000	181,000	-3,764,000	-557,000	1,478,000	928,000	-1,094,000	-558,000	947,000	2,497,000	10,000	-2,691,000	804,000	-449,000	-1,476,000	-598,000
inventory	-478,000	-5,437,000	4,720,000	-542,000	2,274,000	11,115,000	1,333,000	1,443,000	1,306,000	2,348,000	8,450,000	12,327,000	-9,463,000	16,430,000	18,071,000	24,095,000	-27,912,000	-17,077,000	-38,660,000	-13,074,000	-8,831,000	-3,318,000	-3,750,000	-2,475,000	3,163,000	690,000	204,000	2,172,000	-393,000	-50,000	-963,000	-1,611,000	-152,000	-3,150,000	-647,000	-2,610,000	314,000	263,000	-1,676,000	940,000	-261,000	2,652,000	-1,439,000	-1,364,000	-1,122,000	1,112,000	-4,433,000	-1,910,000	863,000	1,826,000	1,391,000
other current assets and prepaid expenses	-5,053,000	2,735,000	-578,000	-7,265,000	-552,000	-3,056,000	8,941,000	60,181,000	-58,902,000	561,000	2,525,000	-9,114,000	2,612,000	15,216,000	166,000	-15,319,000	1,415,000	7,393,000	15,730,000	-1,890,000	-729,000	-5,032,000	2,522,000	-46,000	-574,000	-9,175,000	5,445,000	-6,549,000	-1,000,000	4,692,000	-10,001,000
other assets	457,000	-967,000	680,000	-123,000	7,000	2,378,000	-751,000	-2,687,000	772,000	1,724,000	471,000	-771,000	511,000	-755,000	-373,000	133,000	1,255,000	-177,000	-209,000	-121,000	60,000	104,000	379,000	-243,000	-4,487,000	-15,000	-131,000	-195,000	-19,000	-235,000	-1,134,000	-715,000	1,447,000	1,774,000	-3,000	-509,000	554,000	2,482,000	1,429,000	-1,069,000	428,000	26,000	71,000	-438,000	66,000	4,000	7,000	-37,000	35,000	-62,000	80,000
accounts payable	-3,388,000	11,475,000	-20,215,000	10,899,000	2,789,000	2,637,000	-20,019,000	7,451,000	12,759,000	15,612,000	-5,492,000	-35,651,000	16,143,000	-6,101,000	6,905,000	-73,882,000	62,231,000	33,898,000	20,014,000	-11,888,000	-4,865,000	17,710,000	9,174,000	3,713,000	-1,237,000	2,114,000	-10,206,000	2,574,000	-10,100,000	19,539,000	-2,936,000	-12,856,000	-349,000	-42,605,000	4,994,000	2,107,000	-542,000	-4,787,000	1,479,000	-474,000	1,970,000	436,000	-103,000	1,578,000	465,000	-525,000	-271,000	1,868,000	596,000	-1,761,000	-2,487,000
foreign currency measurement	-1,348,000	-641,000	-6,213,000	1,413,000	1,225,000	-1,060,000	1,342,000	1,037,000	-2,355,000	-8,172,000	6,246,000	2,098,000	2,197,000	-37,000	4,914,000	-3,478,000	946,000	-2,403,000	1,295,000	-2,133,000	56,000	16,000	154,000	-23,000	134,000	-66,000	-11,000	378,000	299,000	-69,000	-28,000	-152,000	-253,000	476,000	-173,000	473,000	1,832,000	152,000	-976,000	-977,000	-1,859,000	790,000	-340,000	290,000	-95,000	349,000	-458,000
accrued expenses and other liabilities	-24,246,000	-19,397,000	41,513,000	4,486,000	-1,047,000	-3,974,000	-6,445,000	-4,474,000	9,547,000	-8,150,000	-12,653,000	-33,801,000	-36,177,000	31,964,000	-16,527,000	-22,034,000	-27,126,000	-7,160,000	41,403,000	43,737,000	3,848,000	-2,333,000	-10,155,000	12,250,000	11,261,000	-6,991,000	-8,829,000	-8,055,000	12,187,000	-16,024,000	2,563,000	20,326,000	13,126,000	34,047,000	-1,672,000	4,413,000
net cash from operating activities	-83,420,000	-34,554,000	-77,079,000	-26,435,000	-35,566,000	-38,294,000	33,109,000	-365,000	-22,647,000	-31,620,000	-32,236,000	-11,477,000	-19,856,000	-5,643,000	33,396,000	-15,453,000	26,037,000	34,258,000	63,011,000	-14,423,000	-43,370,000	-23,866,000	-53,631,000	-48,988,000	-21,883,000	-17,079,000	-35,520,000	-37,607,000	-22,664,000	-33,919,000	-31,896,000	42,842,000	-9,206,000	-31,363,000	-34,055,000	238,793,000	-21,077,000	-15,495,000	-29,046,000	-26,050,000	-11,472,000	-5,925,000	-14,745,000	-5,728,000	-1,927,000	-6,261,000	-11,499,000	-6,588,000	-3,346,000	-3,881,000	-4,685,000
cash flows from investing activities:
investments in investees	335,000	-8,000,000				0	0	0	-5,000,000													0	0	-1,200,000	0	0	-1,000,000	-1,625,000			-3,250,000	-5,671,000	-250,000	-655,000			-89,000	0	-500,000	-4,100,000	0	-10,841,000	-2,500,000	-696,000	0	0	-2,700,000
proceeds from sale of equity securities	0	51,655,000																							230,000	0	1,286,000										0	34,000	1,297,000	18,928,000
proceeds from the sale of property, plant and equipment	114,000	67,000	66,000	55,000	48,000	1,604,000	267,000	522,000	320,000	450,000	631,000	522,000	348,000	51,000	65,810,000	105,000	60,000	53,000	127,000	58,000	7,000	243,000			230,000	299,000	541,000	581,000	303,000	3,095,000	374,000									5,000
capital expenditures	-3,283,000	-3,194,000	-7,937,000	-7,217,000	-4,443,000	-3,022,000	-4,203,000	-6,013,000	-3,037,000	-6,336,000	-7,612,000	-5,379,000	-5,251,000	-6,730,000	-7,234,000	-8,947,000	-9,245,000	-6,797,000	-9,736,000	-11,523,000	-5,626,000	-2,434,000	-3,500,000	-2,932,000	-12,031,000	-6,819,000	-5,973,000	-15,256,000	-7,268,000	-9,537,000	-4,149,000	-3,054,000	-9,812,000	-2,983,000	-1,076,000	-363,000	-1,468,000	-1,606,000	-861,000	-971,000	-937,000	-1,299,000	-755,000	-408,000	-656,000	-233,000	-175,000	-704,000	-707,000	-434,000	-108,000
free cash flows	-86,703,000	-37,748,000	-85,016,000	-33,652,000	-40,009,000	-41,316,000	28,906,000	-6,378,000	-25,684,000	-37,956,000	-39,848,000	-16,856,000	-25,107,000	-12,373,000	26,162,000	-24,400,000	16,792,000	27,461,000	53,275,000	-25,946,000	-48,996,000	-26,300,000	-57,131,000	-51,920,000	-33,914,000	-23,898,000	-41,493,000	-52,863,000	-29,932,000	-43,456,000	-36,045,000	39,788,000	-19,018,000	-34,346,000	-35,131,000	238,430,000	-22,545,000	-17,101,000	-29,907,000	-27,021,000	-12,409,000	-7,224,000	-15,500,000	-6,136,000	-2,583,000	-6,494,000	-11,674,000	-7,292,000	-4,053,000	-4,315,000	-4,793,000
net cash from investing activities	-2,834,000	40,528,000	247,784,000	-7,162,000	-4,395,000	-1,418,000	-3,572,000	-5,491,000	-7,717,000	-7,872,000	-4,682,000			-8,679,000	54,576,000	-8,842,000	-1,106,000	-6,744,000	5,501,000	-11,465,000	-5,619,000	-2,191,000	-3,191,000	-4,132,000	-11,571,000	-6,520,000	-5,146,000	-16,301,000	-9,970,000	-6,442,000	19,486,000	-23,647,000	-10,062,000	7,174,000	-98,095,000	-363,000	-1,545,000	-3,067,000	-264,000		45,292,000	-53,199,000	-649,000	8,430,000	-10,801,000	-4,526,000	-17,872,000	39,143,000	12,100,000
cash flows from financing activities:
issuance of 3.00% convertible senior notes			0	0	230,000,000																																						170,184,000
debt issuance costs			-4,823,000	0	-8,562,000									0								0	0	-7,762,000
share repurchase			-23,759,000	0	-50,000,000
proceeds from the exercise of common stock options	-211,000	88,000	0				28,000				-463,000
borrowings on lines of credit	11,026,000	5,610,000	130,648,000	154,108,000	163,703,000	156,360,000	173,468,000	176,562,000	165,288,000	165,971,000	209,081,000	-964,699,000	1,649,166,000	358,072,000	343,844,000	510,584,000	472,213,000	408,787,000	305,428,000	207,253,000	186,398,000	59,658,000	4,235,000	35,460,000	3,651,000	12,206,000	6,611,000	30,020,000	37,699,000	7,825,000	6,320,000	4,248,000	5,248,000	100,321,000	5,880,000	5,158,000	5,068,000	10,008,000	4,250,000	9,964,000	9,259,000	6,926,000	8,428,000
repayments of lines of credit	-9,841,000	-9,546,000	-141,045,000	-156,015,000	-168,241,000	-160,112,000	-171,391,000	-172,799,000	-175,407,000	-155,741,000	-200,173,000	977,333,000	-1,657,193,000	-357,441,000	-348,325,000	-510,477,000	-479,713,000	-400,766,000	-360,558,000	-194,365,000	-188,009,000	-79,653,000	-43,511,000	-35,313,000	-7,511,000	-8,504,000	-12,420,000	-7,118,000	-6,008,000	-7,517,000	-9,560,000	-41,992,000	-7,349,000	-93,522,000	-5,173,000	-4,849,000	-7,252,000	-8,586,000	-5,985,000	-11,291,000
settlement of convertible notes
net cash from financing activities	-79,489,000	-4,022,000	206,140,000	-2,115,000	20,613,000	-3,751,000	2,105,000	3,462,000	-13,119,000	10,144,000	8,444,000	12,274,000	-7,891,000	832,000	-4,256,000	265,000	-7,192,000	8,108,000	-54,461,000	12,888,000	-1,611,000	-19,995,000	-39,276,000	163,875,000	-3,005,000	4,020,000	49,191,000	22,902,000	31,741,000	2,174,000	960,000	-37,986,000	53,000	14,694,000	4,670,000	13,812,000	7,135,000	-3,905,000	-96,000	17,037,000	2,813,000	-3,317,000	169,641,000	1,048,000	-1,774,000	1,879,000	4,878,000	-8,356,000	-146,000	-9,744,000	105,163,000
effect of exchange rate changes on cash, cash equivalents and restricted cash	1,461,000	2,110,000
net decrease in cash, cash equivalents and restricted cash
cash, cash equivalents and restricted cash at beginning of period	0	445,615,000
cash, cash equivalents and restricted cash at end of period	-164,282,000	449,677,000
supplemental information:
interest paid	6,305,000	13,762,000	9,465,000	392,000	3,125,000	-2,613,000	6,544,000	374,000	3,830,000	401,000	3,465,000	134,000	3,420,000	129,000	3,503,000	194,000	4,689,000	251,000	5,079,000	566,000	5,012,000	5,673,000	4,900,000	511,000	846,000	144,000	641,000	661,000	198,000	550,000	1,619,000	277,000	623,000	1,193,000	156,000	1,568,000	2,451,000	351,000	2,420,000		2,808,000	76,000	242,000		272,000	164,000	177,000		289,000	254,000	65,000
income taxes paid, net of refunds	17,802,000	2,059,000	2,225,000	513,000	1,063,000	4,535,000	-1,508,000	208,000	477,000	3,566,000	-176,000	3,584,000	1,063,000	460,000	1,819,000	2,220,000	1,470,000	-1,051,000			799,000	971,000	1,110,000	1,022,000	-1,368,000	2,959,000	2,292,000
non-cash financing:
shares issued upon the conversion of:
common stock options, warrants, and restricted stock units surrendered in net exercise			0
loss on conversion convertible senior notes			-32,000	0	757,000
redemption of 2025 notes and 2033 senior notes		-174,000	0	0	-146,287,000
net increase in cash, cash equivalents and restricted cash		4,062,000
change in fair value of contingent consideration						-13,000	-1,125,000	-34,000	136,000	-627,000	-754,000	175,000	-106,000	-147,000	-497,000	-102,000	-957,000	-5,323,000	1,083,000	1,111,000	-860,000	-1,109,000	-3,775,000	4,806,000	1,193,000	-15,358,000	1,759,000	-11,213,000	4,367,000	2,371,000	3,093,000	10,758,000	1,753,000	1,635,000	-339,000	5,175,000	19,592,000	1,876,000	2,610,000	2,774,000	252,000	2,577,000	1,344,000	-2,339,000
gain on sale of assets
purchase of marketable securities																												-1,000			-1,000									0	0			3,117,000	-11,806,000	-2,120,000	-14,997,000	0	-30,180,000	-9,998,000	-59,983,000
proceeds from labcorp sale
issuance of 2044 notes
repurchase of 2029 convertible notes
assets acquired by finance leases						-510,000	532,000	-779,000	960,000
operating lease right-of-use assets in exchange for lease obligations
fair value of shares received related to milestone achieved from genedx holdings
contract liabilities						-129,000	-4,000	0	2,000	-256,000	-56,000	-13,000	-4,000	-2,895,000	-5,591,000	-6,635,000	-790,000	-672,000	-691,000	5,425,000	-9,451,000	-19,845,000	-18,942,000	-18,073,000	-19,719,000	-15,454,000	-15,358,000
effect of exchange rate changes on cash and cash equivalents				649,000	-894,000	723,000	-1,129,000	-328,000	1,122,000	1,701,000	-1,146,000	-1,115,000	221,000	-399,000	-874,000	284,000	-447,000	295,000	631,000	82,000	-322,000	-396,000	-37,000	22,000	-204,000	17,000	-81,000	838,000	371,000	506,000	81,000														-241,000	-39,000	95,000		-222,000	45,000	14,000
net decrease in cash and cash equivalents				-35,063,000	-20,242,000				-42,361,000															110,777,000	-36,663,000			-30,168,000	-522,000	-37,681,000
cash and cash equivalents at beginning of period				0	95,881,000	0	0	0	153,191,000	0	0	0	134,710,000	0	0	0	72,211,000	0	0	0	85,452,000	0	0	96,473,000	0	0	91,499,000	0	0	168,733,000	0	0	193,598,000	0	0	96,907,000	0	0	185,798,000	0	0	0	27,361,000			0	71,516,000		0	0	18,016,000
cash and cash equivalents at end of period				-35,063,000	75,639,000	-42,740,000	30,513,000	-2,722,000	110,830,000	-27,647,000	-29,620,000	108,177,000	102,281,000	-13,889,000	82,842,000	-23,746,000	89,503,000	35,917,000	14,682,000	-12,918,000	34,530,000	-46,448,000	-96,135,000	207,250,000	-36,663,000	-19,562,000	99,943,000	-30,168,000	-522,000	131,052,000	-11,369,000	-18,958,000	174,973,000	-9,073,000	-126,975,000	348,192,000	-15,752,000	-22,386,000	156,396,000	29,964,000	36,773,000	-62,535,000	181,596,000		-14,743,000	-8,947,000	47,118,000		8,386,000	-9,030,000	47,879,000
non-cash revenue from the transfer of intellectual property														0
loss on conversion of the 2025 notes														0	0
gain on sale of genedx										-3,194,000	0
deferred income tax provision														7,781,000	-101,000	3,512,000	-1,033,000	13,666,000	946,000
changes in assets and liabilities, net of the effects of acquisitions:
proceeds from sale of investments														0	0	0	8,079,000	0
acquisition of businesses, net of cash acquired
net activity from the exercise of common stock options and warrants
redemption of 2033 senior notes						0	0	0	-3,000,000													0	0	-28,800,000
net increase in cash and cash equivalents						-42,740,000	30,513,000			-27,647,000	-29,620,000	108,177,000	-32,429,000	-13,889,000			17,292,000			-12,918,000	-50,922,000	-46,448,000					8,444,000				-11,369,000	-18,958,000	-18,625,000	-9,073,000	-126,975,000	251,285,000	-15,752,000	-22,386,000	-29,402,000	29,964,000	36,773,000	-62,535,000	154,235,000	3,933,000	-14,743,000	-8,947,000	-24,398,000		8,386,000	-9,030,000	29,863,000
operating lease right-of-use assets obtained in exchange for lease obligations						23,397,000
2025 convertible notes															0
common stock options and warrants, surrendered in net exercise										86,000	527,000											0	0	20,000	0			0	850,000	696,000	25,000	290,000	35,000	2,000	1,000	14,238,000
issuance of common stock for acquisition of modex										0	2,288,000
fair value of shares included in consideration from genedx holdings
realized loss on disposal of fixed assets and sales of equity securities							-631,000	230,000	1,845,000											54,000	102,000
proceeds from sale of genedx											0
acquisition of businesses, net of cash											2,299,000																							15,812,000			12,000	-1,495,000	-200,000		20,450,000	0	78,000	-8,580,000	-8,339,000			-17,648,000	0	0	-10,538,000
fair value of shares received included in consideration from genedx holdings
issuance of common stock
fair value of shares included in consideration from sema4											0
net cash from used in investing activities													-4,903,000
proceeds from the exercise of common stock options and warrants													136,000	201,000	413,000	158,000	308,000	87,000				0	0	-3,000	855,000			0	50,000	1,866,000	4,200,000	-242,000	2,154,000	7,814,000	4,654,000	12,712,000	9,319,000	1,108,000	1,639,000	18,364,000	3,542,000	524,000	995,000	577,000
asset impairment charges
issuance of 2023 convertible notes, including to related parties
operating lease right-of-use assets due to adoption of asu no. 2016-02																						6,186,000	-3,637,000	33,277,000
operating lease liabilities due to adoption of asu no. 2016-02																						6,190,000	-3,695,000	33,744,000
realized gain on disposal of fixed assets and sales of equity securities and other
change in fair value of equity securities and derivative instruments and other
impairment of assets																						0	0	655,000
issuance of convertible notes, including to related parties																						0	0	200,293,000
income taxes paid (received), net of refunds
gain on disposal of fixed assets																							-64,000	284,000	529,000	-234,000	-261,000
issuance of 2033 senior notes, including to related parties																									0
issuance of capital stock for contingent consideration settlement:
opko health europe																												0			0	0	313,000	0
issuance of 2033 senior notes, net, including related parties																											55,000,000
realized gain on equity securities and disposal of fixed assets																												-210,000	524,000	-2,997,000
change in fair value of derivative instruments																												7,550,000	-5,482,000	-4,037,000	5,701,000	-1,235,000	1,423,000	-32,244,000	16,556,000	49,788,000
deferred revenue																												-8,124,000	-16,661,000	-17,357,000	-20,318,000	-18,129,000	-17,809,000	-17,664,000	-18,312,000	282,238,000
maturities of short-term marketable securities																																								25,011,000				14,997,000					45,000,000
acquisition of intangible assets
income taxes paid																												1,578,000	3,473,000	848,000	873,000	5,667,000	1,505,000	626,000	530,000	227,000	-230,000												8,000
transition therapeutics, inc.
opko renal
issuance of stock for investment in xenetic
issuance of capital stock to acquire or contingent consideration settlement:
revenue from receipt of equity																																		-20,000	-60,000	-60,000	-60,000	-60,000	-60,000	-60,000	-60,000	-80,000	-12,540,000			-51,000	-51,000
loss on conversion of 3.00% convertible senior notes																																				321,000				0
gain on deconsolidation of scivac
cash from non-controlling interest																																		0	-691,000	791,000
2033 senior notes																																		28,127,000	12,284,000	79,888,000	0
bio-reference laboratories, inc.
eirgen pharma limited																																		0
realized gain on equity securities
realized gain on sale of equity securities																																		0	0	-216,000	1,000	-1,000	-1,273,000	-18,928,000
(gain) loss on conversion of 3.00% convertible senior notes																																		-1,234,000
prepaid expenses and other current assets																																	-6,883,000	-5,367,000	198,000	944,000	163,000	2,179,000	1,145,000	950,000	491,000	-2,000	-2,570,000	-1,565,000	6,000	-837,000	-481,000	-167,000	317,000	286,000	-379,000
effect of exchange rate on cash and cash equivalents																																	590,000	422,000	505,000	-957,000	-265,000	81,000	4,000	104,000	140,000	-94,000	-12,000
non-cash interest on 2033 senior notes																																		495,000	625,000	1,056,000	1,039,000	1,780,000	1,777,000
(recovery of) benefit from bad debts																																		7,682,000	452,000	174,000	48,000
benefit from inventory obsolescence																																		-27,000	490,000	220,000	190,000	246,000	337,000	486,000	256,000	334,000	939,000
in-process research and development																																					0
deferred income tax (benefit) expense
contingent consideration payments																																					0
pharmsynthez common stock received																																					0	0	6,264,000
issuance of capital stock to acquire:
inspiro																																					0
opko uruguay ltda.
gain on conversion of 3.00% convertible senior notes																																					0
loss on sale of property, plant and equipment																																								4,000
accrued expenses																																					1,997,000	4,344,000	-8,007,000	-6,149,000	2,337,000	5,031,000	-440,000	1,902,000	546,000	-1,340,000	1,253,000	-1,264,000	1,755,000	-649,000	-254,000
payment of series d dividends, including related parties																																								0	0	0	-3,015,000
rxi common stock received																																									0	0	12,500,000
series d preferred stock																																									0	0	24,386,000
issuance of common stock to acquire:
opko biologics
opko brazil																																									0
arama uruguay																																					0	0	159,000
change in fair value of derivatives instruments																																						-10,967,000	10,515,000	-2,202,000	27,793,000	-12,651,000	23,549,000
common stock options and warrants, net exercised																																						2,836,000	657,000
benefit from (recovery of) bad debts																																							-74,000			-52,000	381,000
income taxes paid (refunded)																																							377,000
income from discontinued operations, net of tax
non-cash interest on convertible senior notes																																								1,730,000	1,130,000	1,817,000	1,303,000
deferred income tax (benefit)/provision
changes in assets and liabilities of continuing operations, net of the effects of acquisitions:
cash from operating activities of continuing operations																																								-26,050,000	-11,472,000	-5,925,000	-14,745,000		-2,023,000	-6,104,000	-11,574,000
cash from operating activities of discontinued operations																																													96,000	-157,000	75,000
cash provided (or used) by investing activities from continuing operations
cash from investing activities from discontinued operations
net cash provided (or used) in investing activities
issuance of 3.00% convertible senior notes, net, including related parties																																								0	0
issuance of common stock, net (including related parties) net
purchase of common stock held in treasury																																																0	0
redemption of series a preferred stock (including related parties
benefit from bad debts
changes in assets and liabilities of continuing operations, net of theeffects of acquisitions:
3.00% convertible senior notes
common stock warrants, net exercised																																									0	0	815,000
issuance of common stock, common stock options and warrants to acquire prolor
cytochroma																																									0	0	146,902,000
farmadiet
realized gain on investments available for sale																																										-8,474,000	-2,347,000
proceeds from sale of investments available for sale																																										8,968,000	2,528,000
repayments of lines of credit and capital lease obligations																																										-10,767,000	-6,951,000
supplemental information
cash flows from operating activities
cash provided in operating activities of discontinued operations
income taxes refunded																																											-118,000			203,000	-6,000
silcon																																											436,000
accretion of debt discount related to notes payable																																																0	0	0	2,000
equity based compensation – employees and non-employees
benefit from (recovery of) inventory obsolescence
unrealized gains on derivative instruments																																												-31,000
cash from operating activities from continuing operations																																																-6,307,000
cash from operating activities from discontinued operations
cash from investing activities from continuing operations																																																21,827,000
issuance of common stock, including related parties																																																0	0	0	104,828,000
redemption of series a preferred stock including related parties
payment of series d dividends, including to related parties
repayments of line of credit with related party
cash and cash equivalents at beginning of year
cash and cash equivalents at end of year
(income) income from discontinued operations, net of tax
equity-based compensation - employees and non-employees																																													1,112,000
income from investments in investees																																													468,000	473,000	523,000		301,000	451,000	423,000
benefit from bad debt
revenue from receipt of equity in neovasc
redemption of series a preferred stock																																																	0
borrowings under lines of credit																																																	4,304,000
repayments under lines of credit																																													-9,820,000	-10,798,000	-5,490,000		-4,916,000	-3,018,000	-2,827,000
cash and cash equivalents at beginning period
non-cash financing activities:
issuance of common stock to acquire farmadiet
(recovery of) benefit from bad debt																																														60,000	-151,000
benefit from inventory reserves																																														499,000	255,000
unrealized gain on investments, available for sale
contingent consideration																																														965,000	1,144,000
borrowing under lines of credit																																														11,216,000	10,337,000				3,027,000
proceeds from the exercise of stock options and warrants																																														1,461,000	31,000	470,000	466,000	173,000	135,000
unrealized gain from warrants																																															-1,117,000
cash flows from investing activities
write-off of acquired in-process research and development
foreign currency remeasurement
acquisition of rolapitant
maturities of marketable securities
issuance of series d preferred stock and warrants, including related parties
proceeds from bridge loan with related party
repayment of bridge loan with related party
net change in cash and cash equivalents
income from continuing operations
benefit from (recovery of) bad debt																																																			28,000
changes in:
cash from operating activities from discontinuing operations
investment in neovasc
repayment of line of credit with related party
issuance of capital stock to acquire exakta-opko
equity-based compensation — employees and non-employees																																																		1,744,000	1,754,000
benefit from (reversal of) inventory reserves																																																		294,000	62,000
cash flows from investing activity
net cash from investing activity																																																			-70,629,000
repayments of notes payable and capital lease obligations
impairment of goodwill
equity based compensation — employees and non-employees
foreign exchange
loss on disposal of assets
license of product for equity
issuance of common stock for cash to related party
insurance financing and borrowings on lines of credit

We provide you with 20 years of cash flow statements for OPKO Health stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of OPKO Health stock. Explore the full financial landscape of OPKO Health stock with our expertly curated income statements.

The information provided in this report about OPKO Health stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.